MicrobeWorld App

appsquarebannerad200x200

Microbes After Hours

microbes-after-hours-logo
Click for "Microbes After Hours" videos

Agar Art Contest 2016

AgarArt-MicrobeWorld-200x200

Featured Image

Featured Video

MWV102featured

Join MicrobeWorld

Supporters

ASM House 200X200

Subscribe via Email

subscribe

Vertex hep C drug achieves 75 pct cure rate: study

A closely watched experimental hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal late-stage trial of previously untreated patients, the company said on Tuesday.

The results from the first Phase III study of telaprevir were roughly in line with expectations. Vertex shares, which have slumped recently, rose 14 percent in after-hours trading.

Seventy-five percent of patients who received 12 weeks of telaprevir in combination with current standard treatment of pegylated interferon and ribavirin, followed by either 12 or 36 weeks of standard treatment achieved a sustained virologic response, or SVR, which is tantamount to a cure.
 
 

Comments (0)

Collections (0)

 

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600
American Society For Microbiology © 2014   |   Privacy Policy   |   Terms of Use